Merus Announces First Patient Dosed In LiGeR-HN1, A Phase 3 Trial Evaluating Petosemtamab In Combination With Pembrolizumab In 1L r/m HNSCC
Portfolio Pulse from Benzinga Newsdesk
Merus N.V. has initiated dosing in a Phase 3 trial (LiGeR-HN1) to evaluate petosemtamab in combination with pembrolizumab for treating PD-L1+ recurrent/metastatic head and neck squamous cell carcinoma. The FDA has approved the dosage for further development.
September 30, 2024 | 12:07 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Merus N.V. has dosed the first patient in a Phase 3 trial for petosemtamab combined with pembrolizumab, targeting r/m HNSCC. The FDA has approved the dosage, indicating potential progress in treatment development.
The initiation of a Phase 3 trial and FDA approval of the dosage are significant milestones for Merus, suggesting potential advancements in their treatment pipeline. This could positively impact investor sentiment and the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100